Literature DB >> 20040316

Krabbe disease: an overview.

G M Pastores1.   

Abstract

Krabbe disease (globoid cell leukodystrophy) is a neurodegenerative disorder that is caused by deficiency of the lysosomal enzyme galactosylceramidase. The resulting accumulation of incompletely metabolized galactocerebroside, which is a component of myelin, leads to progressive white matter disease. The severity of signs and symptoms is partly influenced by the causal mutations and corresponding residual enzyme activity. This review explains how the disease might manifest and discusses methods for diagnosis and staging of the disease process. The current understanding of the mechanisms underlying Krabbe disease is summarized, and therapeutic options--including current and investigational approaches--are outlined.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20040316     DOI: 10.5414/cpp47075

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  9 in total

Review 1.  Mesenchymal stem cells as cellular vectors for pediatric neurological disorders.

Authors:  Donald G Phinney; Iryna A Isakova
Journal:  Brain Res       Date:  2014-05-22       Impact factor: 3.252

Review 2.  Biochemical, cell biological, pathological, and therapeutic aspects of Krabbe's disease.

Authors:  Je-Seong Won; Avtar K Singh; Inderjit Singh
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

3.  Synthesis and properties of a photoactivatable analogue of psychosine (beta-Galactosylsphingosine).

Authors:  Ravi S Lankalapalli; Attila Baksa; Károly Liliom; Robert Bittman
Journal:  ChemMedChem       Date:  2010-05-03       Impact factor: 3.466

4.  A HILIC-MS/MS method for simultaneous quantification of the lysosomal disease markers galactosylsphingosine and glucosylsphingosine in mouse serum.

Authors:  Rohini Sidhu; Christina R Mikulka; Hideji Fujiwara; Mark S Sands; Jean E Schaffer; Daniel S Ory; Xuntian Jiang
Journal:  Biomed Chromatogr       Date:  2018-04-26       Impact factor: 1.902

Review 5.  Lysosomal lipid storage diseases.

Authors:  Heike Schulze; Konrad Sandhoff
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-06-01       Impact factor: 10.005

6.  Tests, testing, and tested - we need to critically evaluate the meaning of tests in psychiatry.

Authors:  Douglas M Berger
Journal:  Indian J Psychiatry       Date:  2013-04       Impact factor: 1.759

7.  Developmental regression and irritability.

Authors:  Naif M AlAnazy; Saad A Al-Shahwan; Zeeshan Azmat; Brahim Tabarki
Journal:  Neurosciences (Riyadh)       Date:  2014-07       Impact factor: 0.906

Review 8.  Promoter considerations in the design of lentiviral vectors for use in treating lysosomal storage diseases.

Authors:  Estera Rintz; Takashi Higuchi; Hiroshi Kobayashi; Deni S Galileo; Grzegorz Wegrzyn; Shunji Tomatsu
Journal:  Mol Ther Methods Clin Dev       Date:  2021-11-24       Impact factor: 6.698

Review 9.  Mesenchymal Stem Cell-Based Therapy for Lysosomal Storage Diseases and Other Neurodegenerative Disorders.

Authors:  Shaza S Issa; Alisa A Shaimardanova; Victor V Valiullin; Albert A Rizvanov; Valeriya V Solovyeva
Journal:  Front Pharmacol       Date:  2022-03-02       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.